Triple
T5981230
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Elan Pharmaceuticals |
E133121
|
entity |
| Predicate | coDevelopedWith |
P6901
|
FINISHED |
| Object | Biogen Idec |
E3807
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Biogen Idec | Statement: [Elan Pharmaceuticals, coDevelopedWith, Biogen Idec]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Biogen Idec Context triple: [Elan Pharmaceuticals, coDevelopedWith, Biogen Idec]
-
A.
Biogen
chosen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eisai and Biogen
Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
-
C.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
D.
Alexion Pharmaceuticals
Alexion Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for rare and severe diseases, particularly in the field of complement biology.
-
E.
Genzyme
Genzyme is a biotechnology company best known for developing treatments for rare genetic disorders and other specialty diseases.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c0086f45e8819098f73dd16d45ec9d |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04a67c3248190ba35a7121eb49672 |
completed | March 22, 2026, 8 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c11cd3988c8190aecc690a02c26c25 |
completed | March 23, 2026, 10:58 a.m. |
Created at: March 22, 2026, 4:04 p.m.